secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001846253-25-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q1 2025 revenue $4.2M (+10% YoY), net loss $18.2M; lowers opex guidance
------------------------------------------------------------------------------

- Q1 revenue $4.2M (vs $3.8M in Q1 2024); net loss $18.2M ($0.17/share) vs $19.0M ($0.19/share) prior year.
- Cash $43.6M at March 31, 2025; FY2025 revenue guidance reaffirmed $20-25M; opex guidance lowered to $85-90M from $90-95M.
- Entered three new platform license agreements (Wyss, Takis, Orion); Orion deal includes $250K upfront and >$55M milestones.
- Post-quarter asset sale to Angelini Pharma for Kv7.2 program: $3M upfront, >$170M milestones plus royalties.
- Partner updates: Immunovant batoclimab positive MG/CIDP results; Teva Phase 2 celiac trial; Sugemalimab EMA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625325000053/0001846253-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625325000053/oabi-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001846253-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer